EN DE
Watch Central Proteina Prima Tbk for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Central Proteina Prima Tbk (CPRO) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Central Proteina Prima Tbk stock IDR 83, price IDR 33, upside +150.9%, quality 56 out of 100. Rating: strongly undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive ID · ISIN ID1000105000

CP Central Proteina Prima Tbk logo Thin data Nov 16, 2026

Central Proteina Prima Tbk

CPRO · JK

Cheap (60% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Follow free in the weekly email
Fair value 82.80 IDR · Strongly undervalued 
Low debt 
Generates free cash flow 
Ranks above peers (11/14) 
Even on cautious assumptions the value is 59% above the price (52.40 IDR). 
Quality 56/100 
Mixed Growth (revenue 5y +5.6 %/yr in IDR) 
Thin margins · 3.2% net margin (TTM) 
Falling price (downtrend) 
Narrow moat 41/100 · thin data
Thin data 
⟳ Cyclical
Watch Central Proteina Prima Tbk for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

126.00 IDR 30.00 IDR Fair Value 82.80 IDR Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 30.00 IDR – 126.00 IDR · fair‑value band 52.40 IDR – 120.84 IDR · the 33.00 IDR price screens below the 82.80 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.

Follow Central Proteina Prima Tbk in your weekly email

Every Wednesday you see whether Central Proteina Prima Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Central Proteina Prima Tbk, together with its subsidiaries, operates as an integrated aquaculture shrimp and food producer company in Indonesia, India, Vietnam, China, Japan, the United States, Canada, the United Kingdom, Belgium, France, the Netherlands, Germany, and New Zealand.

Show moreShow less

The company operates through Feeds, Food Products, and Others segments. It engages in the industry, livestock and agriculture, farming, hatchery, and trading and services, as well as production and trading of shrimp, fish feeds and pet food.

The company also offers shrimp feed, fish feed, cat food, dog food, fish food, bird food, rabbit food, probiotic products, fish additives, disinfectants, fish hatchery, shrimp hatchery, medicines for shrimp and fish, and probiotic for shrimp medicines, as well as is involved in the cold storage and trading of shrimp, and an investment holding business.

The company was formerly known as PT Central Proteinaprima Tbk and changed its name to PT Central Proteina Prima Tbk in June 2014. The company was incorporated in 1980 and is headquartered in Jakarta Selatan, Indonesia.

Stock analysis

Central Proteina Prima Tbk (CPRO) currently trades at 33.00 IDR, while our model-based Fair Value estimate is 82.80 IDR, implying the stock looks roughly 60% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 156.51 IDR per share, and 21 of the 25 models we run sit above the 33.00 IDR price.

Bear case: the Asset-Based group reads lowest at 42.50 IDR, and 4 of the 25 models stay below the price. Data coverage for this calculation is low.

Scenario range: 52.40 IDR (bear) to 120.84 IDR (bull), the price of 33.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Consumer Defensive sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Central Proteina Prima Tbk reported revenue of 9.9T IDR in FY2025 versus 8.0T IDR in FY2021, a compound +5.5%/yr. Reported net income was 424B IDR in FY2025, compounding −33.8%/yr from FY2021.

Key figures

Market cap 2.0T IDR (≈ $108M) Micro · P/E ratio 6.5 · P/S ratio 0.19 · EPS (TTM) 5.40 IDR · Dividend yield 0.0% · Net margin 3.2% · Return on equity 8.2% · Return on assets (EBIT) 11.4% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 10% fair-value upside, at 151%, CPRO screens cheaper than that median.

Fair Value models

Bear 52.40 IDR Fair Value 82.80 IDR Bull 120.84 IDR
Price 33.00 IDR · Upside +150.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (4.76 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 31.80 IDR 39.23 IDR 47.21 IDR 81
Growth DCF 31.95 IDR 38.58 IDR 45.43 IDR 79
Owner Earnings 22.99 IDR 28.21 IDR 33.84 IDR 77
All 25 models by family
DCF Models
FCF DCF 31.80 IDR 39.23 IDR 47.21 IDR 81
Owner Earnings 22.99 IDR 28.21 IDR 33.84 IDR 77
5Y Revenue Exit 78.09 IDR 126.78 IDR 187.54 IDR 71
5Y EBITDA Exit 89.16 IDR 146.46 IDR 210.97 IDR 74
5Y P/E Exit 65.19 IDR 103.86 IDR 142.50 IDR 70
10Y Revenue Exit 51.50 IDR 83.15 IDR 123.17 IDR 65
10Y EBITDA Exit 59.08 IDR 93.36 IDR 136.25 IDR 67
10Y P/E Exit 47.55 IDR 71.26 IDR 98.01 IDR 63
Earnings-Based
Graham-Dodd 48.36 IDR 115.57 IDR 149.07 IDR 63
PEG = 1.0 20.30 IDR 29.00 IDR 37.70 IDR 55
EPV 69.80 IDR 76.60 IDR 81.94 IDR 72
Dividend Discount
Gordon GGM 0.0300 IDR 0.0400 IDR 0.0500 IDR 67
DDM Multi-Stage 0.0300 IDR 0.0400 IDR 0.0500 IDR 65
Multiples
P/E Multiple 112.01 IDR 149.34 IDR 186.68 IDR 61
P/S Multiple 90.67 IDR 120.90 IDR 151.12 IDR 56
P/B Multiple 94.43 IDR 125.91 IDR 157.38 IDR 53
EV/EBIT 160.03 IDR 221.93 IDR 283.84 IDR 64
EV/EBITDA 142.09 IDR 198.02 IDR 253.94 IDR 66
EV/Revenue 106.87 IDR 163.67 IDR 220.48 IDR 52
Asset-Based
NCAV (Graham) 31.72 IDR 42.50 IDR 63.43 IDR 52
Growth DCF
Growth DCF 31.95 IDR 38.58 IDR 45.43 IDR 79
Rev-Margin DCF 78.09 IDR 126.52 IDR 177.95 IDR 71
Economic Profit
Residual Income 49.18 IDR 52.38 IDR 58.19 IDR 75
ROIC Compounder 70.38 IDR 78.87 IDR 86.95 IDR 71
Growth Earnings
Growth-Adj P/E 85.18 IDR 121.69 IDR 158.20 IDR 66

The fair value above starts from this blend and is adjusted for a cyclical peak year.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 54
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 58
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 48/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic). Over 10 years: +1.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−20.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−20.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 9%
⚠ Revenue per share shrinking 3.5%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +21.9% a year for the price.

Watch CPRO, get fair value alerts →

Compare Central Proteina Prima Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 299 stocks

Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside +150.9% · Top 25%
Profitability
Return on equity (12 months) 8.2% · Above median
Return on assets 5.9% · Above median
Net margin (12 months) 3.2% · Below median
Operating margin (12 months) 7.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) 9.8% · Above median
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Farm Products median · lower = cheaper

P/E (12 months) 6.5× · Cheapest 25%
P/B 0.52× · Cheapest 25%
P/S (12 months) 0.19× · Cheapest 25%
Price / free cash flow (fiscal year) 13.9× · Pricier than median
EV/EBITDA 2.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 25
FUTURE (revenue growth)49 · sector 22
PAST (return on equity)33 · sector 18
HEALTH (low debt)100 · sector 94
DIVIDEND (yield)0 · sector 43

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Farm Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Charoen Pokphand Foods Public Company CPF 19.95 THB 41.23 THB +107% vs CPRO
Tyson Foods, Inc TSN $63.65 $91.17 +43% vs CPRO
Mowi ASA MOWI kr 226.80 kr 273.63 +21% vs CPRO
Muyuan Foods Group 002714 ¥45.82 ¥53.02 +16% vs CPRO
United Plantations Berhad 2089 31.54 MYR 34.69 MYR +10% vs CPRO
Archer-Daniels-Midland Company ADM $69.47 $61.55 −11% vs CPRO
Wens Foodstuff Group 300498 ¥17.54 ¥12.08 −31% vs CPRO
Fujian Wanchen Food Group 300972 ¥136.90 ¥88.62 −35% vs CPRO
Bunge Global SA BG $95.60 $61.59 −36% vs CPRO
SalMar ASA SALM kr 585.50 kr 260.28 −56% vs CPRO

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Central Proteina Prima Tbk: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Central Proteina Prima Tbk Fair Value". https://www.fairvalue-calculator.com/stock/CPRO

Frequently asked questions

Is Central Proteina Prima Tbk (CPRO) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of 82.80 IDR versus a price of 33.00 IDR, about +151% upside (undervalued).
What is the fair value of CPRO?
Our model-based fair value for Central Proteina Prima Tbk is 82.80 IDR (as of Nov 16, 2026), built from audited fundamentals. The current price: 33.00 IDR.
What is the quality score of CPRO?
Central Proteina Prima Tbk has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Central Proteina Prima Tbk (CPRO)?
Our model-based price target is the fair value of 82.80 IDR (as of Nov 16, 2026) from 25 valuation models. Cautious scenario 52.40 IDR, optimistic scenario 120.84 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Central Proteina Prima Tbk stock forecast for 2026?
Our models put fair value at 82.80 IDR, about +151% upside versus a price of 33.00 IDR (undervalued). Cautious scenario 52.40 IDR, optimistic scenario 120.84 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Central Proteina Prima Tbk (CPRO)?
Central Proteina Prima Tbk reported trailing-twelve-month revenue of about 10.3T IDR (latest available figure, as of Nov 16, 2026).
Does Central Proteina Prima Tbk pay a dividend?
Central Proteina Prima Tbk currently shows a dividend yield of 0.01% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Central Proteina Prima Tbk (CPRO)?
Central Proteina Prima Tbk has a dividend yield of 0.0%.
What growth is priced into Central Proteina Prima Tbk (CPRO)?
For today's price to be fair in a discounted-cash-flow model, Central Proteina Prima Tbk would have to grow free cash flow by 25.1 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 5.6 % per year. As of Nov 16, 2026.
What discount rate (WACC) does the fair value of CPRO use?
Our models discount Central Proteina Prima Tbk at 15.0 %: a base by market capitalisation (micro), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Central Proteina Prima Tbk that is +25.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has Central Proteina Prima Tbk (CPRO) delivered so far?
Over the past 5 years revenue at Central Proteina Prima Tbk grew 5.6 % a year. The price currently implies free-cash-flow growth of +25.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Central Proteina Prima Tbk (CPRO) growing?
The median revenue growth in the sector is +4.0 % a year. That is the yardstick for the growth priced into Central Proteina Prima Tbk (+25.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Central Proteina Prima Tbk (CPRO)?
The free-cash-flow yield on the price is 7.21 %: that much free cash flow Central Proteina Prima Tbk produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Central Proteina Prima Tbk (CPRO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Central Proteina Prima Tbk it is 82.80 IDR per share (as of Nov 16, 2026), against a price of 33.00 IDR. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Central Proteina Prima Tbk stock overvalued or undervalued in 2026?
As of Nov 16, 2026, CPRO trades below its calculated fair value: price 33.00 IDR, fair value 82.80 IDR, a gap of about +151% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CPRO?
No. The price is what the market pays today (33.00 IDR); the fair value is what the company's own numbers justify (82.80 IDR). For Central Proteina Prima Tbk the two are 49.80 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Central Proteina Prima Tbk worth?
The market values Central Proteina Prima Tbk at about 2.0T IDR (market capitalisation, as of Nov 16, 2026). Per share that is 33.00 IDR; our models calculate a fair value of 82.80 IDR per share.
What do the bullish and bearish scenarios say about CPRO?
Our models span a range for Central Proteina Prima Tbk: cautious scenario 52.40 IDR, base 82.80 IDR, optimistic 120.84 IDR per share (as of Nov 16, 2026, price 33.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CPRO?
Central Proteina Prima Tbk trades at a price-to-earnings ratio of 6.5 (as of Nov 16, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 82.80 IDR is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2018 to 2025), reported earnings: 7.8. Other multiples: P/B 0.5, P/S 0.2, EV/EBITDA 2.1.
How solid is the balance sheet of Central Proteina Prima Tbk (CPRO)?
Balance-sheet figures for Central Proteina Prima Tbk (as of Nov 16, 2026): return on equity 8.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is CPRO from its 52-week high?
Central Proteina Prima Tbk trades at 33.00 IDR, about 62% below its 52-week high of 86.00 IDR and 10% above the low of 30.00 IDR (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 82.80 IDR is for.
Which stocks are comparable to Central Proteina Prima Tbk?
From the same area (Consumer Defensive) we also value Muyuan Foods Group, Archer-Daniels-Midland Company, Tyson Foods, Inc, Bunge Global SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Central Proteina Prima Tbk stock attractive at the current price?
The data as of Nov 16, 2026: price 33.00 IDR, calculated fair value 82.80 IDR (+151%), Quality Score 56/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CPRO calculated?
We run Central Proteina Prima Tbk through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 82.80 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Central Proteina Prima Tbk currently trades 60% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Central Proteina Prima Tbk (CPRO)?
The closing price on Nov 17, 2026 was 33.00 IDR. Our model-based fair value is 82.80 IDR, about +151% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Central Proteina Prima Tbk right now?
The price is below even our cautious bear case (52.40 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (52.40 IDR to 120.84 IDR) leaves room in how you read the outcome.

Key figures of Central Proteina Prima Tbk

How large is the market capitalisation of Central Proteina Prima Tbk (CPRO)?
The market capitalisation of Central Proteina Prima Tbk is 2.0T IDR (≈ $108M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Central Proteina Prima Tbk (CPRO)?
The price-to-sales ratio of Central Proteina Prima Tbk is 0.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Central Proteina Prima Tbk (CPRO)?
Earnings per share at Central Proteina Prima Tbk are 5.40 IDR (price ÷ EPS = P/E 6.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Central Proteina Prima Tbk (CPRO)?
The dividend yield of Central Proteina Prima Tbk is 0.0% (payout 0.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Central Proteina Prima Tbk (CPRO)?
The net margin of Central Proteina Prima Tbk is 3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Central Proteina Prima Tbk (CPRO)?
The return on equity (ROE) of Central Proteina Prima Tbk is 8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Central Proteina Prima Tbk (CPRO)?
On an EBIT basis the return on assets of Central Proteina Prima Tbk is 11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Central Proteina Prima Tbk (CPRO)?
The operating margin of Central Proteina Prima Tbk is 7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Central Proteina Prima Tbk (CPRO)?
Revenue at Central Proteina Prima Tbk is growing 9.8% versus a year earlier (3y avg +6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Central Proteina Prima Tbk (CPRO)?
Earnings per share at Central Proteina Prima Tbk are down 30.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Central Proteina Prima Tbk (CPRO) carry?
The net debt of Central Proteina Prima Tbk is 1.5T IDR (fiscal year 2025, ≈ 10.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Central Proteina Prima Tbk in the live analysis

One click puts Central Proteina Prima Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.